arsenic trioxide oral (QTX-2101)
/ Quetzal Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 02, 2025
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
(GlobeNewswire)
- "This global, multicenter, randomized, controlled study will compare QTX-2101 to standard-of-care therapy in patients with newly diagnosed APL."
New P3 trial • Acute Promyelocytic Leukemia
1 to 1
Of
1
Go to page
1